-
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
02 Apr 2024 11:26 GMT
… targeting CS-AKI Arch Biopartners is currently sponsoring a … website. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners' science and technologies … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
18 Mar 2024 11:28 GMT
… Science Advances website. About Arch Biopartners Arch Biopartners Inc. is a late … . For more information on Arch Biopartners' science and technologies, please … . Additional information relating to Arch Biopartners Inc., including our most recent …
-
Arch Biopartners announces Univ of Calgary joins with phase II trial of LSALT peptide to treat cardiac surgery─associated acute kidney injury
18 Mar 2024 11:52 GMT
Arch Biopartners Inc, a late-stage clinical … into the trial. The Arch Biopartners team is currently working with …
-
Arch Biopartners begins subject dosing in Turkey for kidney injury trial
08 Mar 2024 13:05 GMT
Arch Biopartners has initiated subject recruitment and … in the country.
The Arch Biopartners team is coordinating with Canadian …
-
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
07 Mar 2024 12:26 GMT
… (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … mortality. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners' science and technologies … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
27 Feb 2024 12:25 GMT
… (endogenous toxins). About Arch Biopartners Arch Biopartners Inc. is a late-stage … . For more information on Arch Biopartners' science and technologies, please … . Additional information relating to Arch Biopartners Inc., including our most recent …
-
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
10 Jan 2024 12:26 GMT
… (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … mortality. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners' science and technologies … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
03 Jan 2024 12:33 GMT
… Muruve, CEO of Arch Biopartners Inc: “Following the … mortality. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners' science and technologies … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
21 Dec 2023 12:30 GMT
… (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … 20205). About Arch Biopartners Arch Biopartners Inc. is a late … For more information on Arch Biopartners' science and … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
13 Dec 2023 12:25 GMT
… Muruve, CEO of Arch Biopartners Inc: “The clinical trial … , 20205). About Arch Biopartners Arch Biopartners Inc. is a late … For more information on Arch Biopartners' science and technologies … information relating to Arch Biopartners Inc., including our most …